Chebulinic Acid and its Enriched Fraction from the Fruits of Terminalia Chebula for Treatment of Benign Prostatic Hyperplasia (BPH) and its Preparation thereof

• A plant-based therapeutic approach using Chebulinic acid and its enriched fraction from Terminalia chebula for the management and treatment of benign prostatic hyperplasia (BPH), offering an alternative to existing drug therapies.
• Enables development of a standardized, effective, and potentially safer and more affordable solution for BPH symptom management, supported by preclinical evidence.

• A standardized Chebulinic-acid enriched fraction derived from Terminalia chebula fruits is disclosed for the prevention and treatment of benign prostatic hyperplasia (BPH) and associated symptoms.
• Cost-effective and scalable processes are described for isolating Chebulinic acid and Ellagic acid without the use of complex chromatographic methods.
• Formulations of the enriched fraction demonstrate therapeutic efficacy in preclinical BPH models, supporting their potential in prostate health management.

• Offers a plant-derived, potentially safer and cost-effective alternative to conventional BPH therapies, with reduced reliance on synthetic drugs.
• Uses a scalable, non-chromatographic extraction process, enabling easier translation to commercial manufacturing and improved affordability.